BLACKLEDGER Investing Watch: ABOS, EVGO, AVGO
BLACKLEDGER's latest investing watch update tracks ABOS, EVGO, AVGO, RXRX, NVDA, MSTR from the active public watchlist. This post is built from public-safe status data, in-house public signal labels, and outside public source context. It is designed to help readers understand what is happening around each asset without exposing private research methods.
Investing Watch Data
The dedicated feed category for this update is Investing. The latest public scan timestamp is 2026-06-17T08:00:48.027718+00:00.
- ABOS (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- EVGO (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- AVGO (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- RXRX (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- NVDA (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- MSTR (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- LCID (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- URG (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
Educational Context: How To Use This Page
This page is not a trade instruction. It is an educational research brief. Readers can use it to understand company or project background, public market context, public status labels, and relevant outside-source headlines before doing their own due diligence.
ABOS Public Research Bio
Name: Acumen Pharmaceuticals, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
- Latest public price/reference: $2.3
- Public market capitalization: $165.40M
- Recent public volume/reference: 412.04K
- One-month public movement: -2.75%
- Sector/category: Healthcare
Why ABOS Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease — Exec Edge
- Acumen Pharmaceuticals Inc (ABOS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... — GuruFocus.com
- Acumen Pharmaceuticals Q1 Earnings Call Highlights — MarketBeat
- Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner — Zacks
EVGO Public Research Bio
Name: EVgo, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
EVgo, Inc. owns and operates a direct current fast charging network for electric vehicles in the United States. It offers electricity directly to drivers; original equipment manufacturer charging and related services; and commercial charging. The company also provides ancillary services, such as customization of digital applications, charging data integration, access to chargers behind parking lot or garage pay gates, microtargeted advertising, and charging reservations; and hardware, design, and construction services for charging sites, as well as ongoing operations, maintenance, and networking and software integration solutions through eXtend. In addition, it offers PlugShare, such as data, research, and advertising services and equipment procurement and operational services. The company was founded in 2010 and is headquartered in El Segundo, California. EVgo, Inc. operates as a subsidiary of EVgo Holdings LLC.
- Latest public price/reference: $1.99
- Public market capitalization: $627.72M
- Recent public volume/reference: 2.99M
- One-month public movement: -12.91%
- Sector/category: Consumer Cyclical
Why EVGO Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- High gas prices have more Americans opting for EVs: ChargePoint data — Yahoo Finance
- SolarEdge, Shoals, and EVgo Shares Plummet, What You Need To Know — StockStory
- EVgo (EVGO) Appoints Amber Scott as Chief Accounting Officer — Insider Monkey
- 2 Growth Stocks Set to Flourish and 1 Facing Headwinds — StockStory
AVGO Public Research Bio
Name: Broadcom Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
Broadcom Inc. designs, develops, and supplies various semiconductor devices and infrastructure software solutions internationally. The company operates in two segments: Semiconductor Solutions and Infrastructure Software. The company offers networking connectivity, such as custom silicon solutions, ethernet switching & routing, ethernet NIC controllers, physical layer devices, and fiber optic components; wireless device connectivity, including RF semiconductor devices, connectivity solutions, custom touch controllers, and inductive charging ASICS; servers and storage system solutions, such as PCIE switches, SAS & raid products, fibre channel products, and HDD & SSD solutions; broadband solutions, includes set-top box, and broadband access; and industrial. The company also offers a private cloud software portfolio, including the VMware Cloud Foundation, Edge, vSphere foundation, telco cloud platform, private AI, live recovery, applicatio
- Latest public price/reference: $376.8
- Public market capitalization: $1792.23B
- Recent public volume/reference: 29.36M
- One-month public movement: -22.55%
- Sector/category: Technology
Why AVGO Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Qualcomm Stock's Next Chapter Might Be Written In The Cloud — Trefis
- Stock Market Today, June 16: Nvidia, Broadcom, and Micron Technology Lead Drop in Nasdaq — Motley Fool
- Analysts' Top S&P 500 Stocks to Buy Now — Kiplinger
- Stocks Indexes Finish Mostly Lower as Chipmakers Retreat — Barchart
RXRX Public Research Bio
Name: Recu[redacted]on Pharmaceuticals, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
Recu[redacted]on Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reve[redacted]ble, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and h[redacted]tology oncology. Its preclinical stage product includes REC-7735 for the treatment of
- Latest public price/reference: $3.185
- Public market capitalization: $1.69B
- Recent public volume/reference: 15.41M
- One-month public movement: -7.28%
- Sector/category: Healthcare
Why RXRX Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Why Recu[redacted]on Pharmaceuticals (RXRX) Dipped More Than Broader Market Today — Zacks
- X-Energy (XE) Powers 13.5% as Cathie Wood Gobbles More Stake — Insider Monkey
- Cathie Wood Buys $444 Million in SpaceX, Dumps Tesla and AMD — GuruFocus.com
- Recu[redacted]on Pharmaceuticals (RXRX) Stock Valuation After AI Drug Discovery And REC-1245 REC-4881 Updates — Simply Wall St.
NVDA Public Research Bio
Name: NVIDIA Corporation. Market class: stock. Public bias: Bear. Public tier: Extended.
NVIDIA Corporation operates as a data center scale AI infrastructure company in the United States, Taiwan, China, Hong Kong, Europe, and internationally. It operates through Compute & Networking, and Graphics segments. The Compute & Networking segment provides data center accelerated computing and networking platforms and artificial intelligence solutions and software, and automotive platforms and autonomous and electric vehicle solutions, including software. The Graphics segment offers GeForce GPUs for gaming and PCs; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics. The company's products are used in gaming, professional visualization, data center, and automotive markets. It sells its products to original equipment manufacturers, original device manufacturers, system integrators and distributors, independent software vendors, cloud service providers, add-in board manufacturers, distributors, automotive manufacturers and tier
- Latest public price/reference: $207.3
- Public market capitalization: $5023.68B
- Recent public volume/reference: 125.09M
- One-month public movement: -4.11%
- Sector/category: Technology
Why NVDA Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- SpaceX closes in on Amazon in sprint toward $3 trillion — Yahoo Finance
- SpaceX becomes retail's biggest IPO trade: Chart of the Day — Yahoo Finance
- Nvidia CEO Jensen Huang Just Announced Fantastic News to Microsoft Stock Investors — Motley Fool
- Coherent (COHR) Wins Up To $50 Million For Texas AI Chip Expansion — Simply Wall St.
MSTR Public Research Bio
Name: Strategy Inc. Market class: stock. Public bias: Bear. Public tier: Extended.
Strategy Inc, together with its subsidiaries, operates as a bitcoin treasury company in the United States, Europe, the Middle East, Africa, and internationally. It offers investors varying degrees of economic exposure to Bitcoin by offering a range of securities, including equity and fixed income instruments. The company also provides AI-powered enterprise analytics software, including Strategy One, which provides non-technical users with the ability to directly access novel and actionable insights for decision-making. In addition, the company provides Strategy Mosaic, a universal intelligence layer that offers enterprises with consistent definitions and governance across data sources, regardless of where that data resides or which tools access it. The company was formerly known as MicroStrategy Incorporated and changed its name to Strategy Inc in August 2025. The company was incorporated in 1989 and is headquartered in Tysons Corner, V
- Latest public price/reference: $122.8
- Public market capitalization: $43.60B
- Recent public volume/reference: 17.71M
- One-month public movement: -9.19%
- Sector/category: Technology
Why MSTR Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- BlackRock is launching a bitcoin ETF that pays you — Yahoo Finance Video
- How the bitcoin, ethereum playbook is evolving for Strategy and Bitmine — Yahoo Finance Video
- Analysts are watching key Bitcoin level for next bull run — TheStreet
- Bitcoin, Ethereum, XRP, Dogecoin Cool Off As 'Extreme Fear' Prevails: Analyst Says 'We'll Be Testing New Lows' If BTC Fails To Hold This Level — Benzinga
What The Public Data Shows
The public feed highlights ticker status, market class, directional bias, score, tier, confidence, company or project profile, public market references, and outside-source headlines. These fields support a deeper view of BLACKLEDGER's public research feed while keeping private methods undisclosed.
Why This Category Matters
The Investing section gives readers a focused path through the market: buying watch content for constructive candidates, selling watch content for defensive movement, investing content for higher-quality public watch names, and market trend notes for broader context.
Research-Only Notice
BLACKLEDGER content is market research only. There is no live execution signal, no recommendation to buy or sell, and no financial advice. Readers should perform their own due diligence and consult licensed professionals before making financial decisions.
Research-only. No execution signal. Not financial advice.